Two words: one dose. If the first studies are born
Post# of 72436
![Avatar](/images/ProfileImages/424989898_3046_Avatar jpeg2.jpg)
Brilacidin, if proven to be effective, potentially has a much broader range of applications. Just look at what they're discussing -- opthalmic and otitis studies. What if every cataract surgery includes a little jolt of Brilacidin into the eye? What if ear infections are treated by Brilacidin drops? How can one claim equivalent value for a multi-dose antibiotic for one specific type of infection (methicillin-resistant) with a SINGLE-dose antibiotic that treats multiple infections, with multiple potential applications, which seemingly will have far fewer problems with creating resistant bacteria, and which also seems to have anti-inflammatory properties (more about which we will know when the Bril-OM trial gives us some results)?
As far as Leo "admitting" that the antibiotic field is crowded -- really? Source, please. I don't recall any such thing.
And I doubt that anyone who is a researcher in the field would say that the world doesn't need any new antibiotics. In fact, isn't the FDA offering incentives for exactly that kind of research? **cough QIDP cough**
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)